【投融资动态】赜灵生物B++轮融资，投资方为国生资本

Core Insights - Chengdu Zeling Biopharmaceutical Technology Co., Ltd. has completed a B++ round of financing, with the amount undisclosed, and the investment firm involved is Guosheng Capital [1][2]. Financing Details - The B++ round financing was announced on November 9, 2025, with Guosheng Capital as the investor [2]. - Previous financing rounds include: - B+ round on August 4, 2025, with nearly 400 million RMB raised [2]. - B round on November 23, 2023, with undisclosed amounts [2]. - A+ round on October 14, 2022, with undisclosed amounts [2]. - A round on December 6, 2021, raising 107 million RMB [2]. - Angel round on January 19, 2021, with undisclosed amounts [2]. Company Focus - Zeling Biopharmaceutical specializes in the research and development of first-in-class and best-in-class innovative drugs, focusing on unmet clinical needs in areas such as malignant tumors, inflammation, and autoimmune diseases [1][2]. - The company is led by Professor Chen Lijuan from the State Key Laboratory of Biotherapy at West China Hospital of Sichuan University and collaborates with Guizhou BaiLing, a listed company, leveraging multidisciplinary research advantages [2].